Prometheus Biosciences (NASDAQ:RXDX) Price Target Raised to $144.00
Prometheus Biosciences (NASDAQ:RXDX) Price Target Raised to $144.00
Prometheus Biosciences (NASDAQ:RXDX – Get Rating) had its price target raised by The Goldman Sachs Group from $117.00 to $144.00 in a report issued on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's price target would suggest a potential upside of 31.30% from the company's previous close.
据Benzinga报道，在周二发布的一份报告中，高盛将普罗米修斯生物科学公司(纳斯达克：RXDX-GET评级)的目标价从117.00美元上调至144.00美元。该公司目前对这家生物制药公司的股票给予“买入”评级。高盛的目标股价表明，该公司较前一交易日收盘价有31.30%的潜在上行空间。
Other equities research analysts also recently issued research reports about the stock. Stifel Nicolaus lifted their target price on shares of Prometheus Biosciences from $50.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 1st. Credit Suisse Group lifted their price target on shares of Prometheus Biosciences from $59.00 to $142.00 and gave the company an "outperform" rating in a report on Thursday, December 8th. Royal Bank of Canada boosted their target price on shares of Prometheus Biosciences from $66.00 to $111.00 in a report on Wednesday, December 7th. Piper Sandler upped their price target on shares of Prometheus Biosciences from $67.00 to $114.00 in a report on Wednesday, December 7th. Finally, BTIG Research upped their price target on shares of Prometheus Biosciences from $74.00 to $181.00 and gave the company a "buy" rating in a report on Thursday, December 8th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $117.10.
其他股票研究分析师最近也发布了关于该股的研究报告。Stifel Nicolaus在11月1日(星期二)的一份研究报告中将普罗米修斯生物科学公司的股票目标价从50.00美元上调至55.00美元，并给予该股“买入”评级。瑞士信贷集团在12月8日周四的一份报告中将普罗米修斯生物科学公司的股票目标价从59美元上调至142.00美元，并给予该公司“跑赢大盘”的评级。在12月7日周三的一份报告中，加拿大皇家银行将普罗米修斯生物科学公司的股票目标价从66美元上调至111.00美元。派珀·桑德勒在12月7日周三的一份报告中将普罗米修斯生物科学公司的股票目标价从67美元上调至114.00美元。最后，BTIG Research在12月8日星期四的一份报告中将普罗米修斯生物科学公司的股票目标价从74美元上调至181.00美元，并给予该公司“买入”评级。根据MarketBeat.com的数据，九位投资分析师对该股的评级为买入，该公司的共识评级为买入，共识目标价为117.10美元。
Prometheus Biosciences Stock Performance
普罗米修斯生物科学公司股票表现
NASDAQ RXDX opened at $109.67 on Tuesday. The company has a quick ratio of 11.19, a current ratio of 11.19 and a debt-to-equity ratio of 0.11. The company has a 50-day simple moving average of $98.90 and a two-hundred day simple moving average of $66.80. The firm has a market cap of $4.60 billion, a price-to-earnings ratio of -32.74 and a beta of -0.46. Prometheus Biosciences has a 12-month low of $21.50 and a 12-month high of $122.75.
纳斯达克RXDX周二开盘报109.67美元。该公司的速动比率为11.19，流动比率为11.19，债务权益比为0.11。该公司的50日简单移动均线切入位98.90美元，200日简单移动均线切入位66.80美元。该公司的市值为46亿美元，市盈率为-32.74倍，贝塔系数为-0.46。普罗米修斯生物科学公司的12个月低点为21.5美元，12个月高位为122.75美元。
Insider Activity at Prometheus Biosciences
普罗米修斯生物科学公司的内部活动
In other news, CEO Mark C. Mckenna sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $118.99, for a total transaction of $2,974,750.00. Following the completion of the sale, the chief executive officer now owns 55,144 shares in the company, valued at approximately $6,561,584.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Keith W. Marshall sold 5,000 shares of the company's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $119.00, for a total transaction of $595,000.00. Following the transaction, the chief financial officer now directly owns 9,811 shares of the company's stock, valued at approximately $1,167,509. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Mark C. Mckenna sold 25,000 shares of the business's stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $118.99, for a total transaction of $2,974,750.00. Following the completion of the sale, the chief executive officer now owns 55,144 shares in the company, valued at $6,561,584.56. The disclosure for this sale can be found here. Company insiders own 3.40% of the company's stock.
在其他新闻方面，首席执行官马克·C·麦肯纳在1月17日星期二的一次交易中出售了2.5万股该公司的股票。这些股票以118.99美元的平均价格出售，总成交金额为2974,750.00美元。出售完成后，首席执行官现在拥有该公司55,144股，价值约6,561,584.56美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可以通过这个环节。在其他新闻方面，首席财务官基思·W·马歇尔在1月17日星期二的一次交易中出售了5,000股公司股票。这些股票以119.00美元的平均价格出售，总成交额为595,000.00美元。交易完成后，首席财务官现在直接持有该公司9811股股票，价值约1,167,509美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。此外，首席执行官马克·C·麦肯纳在1月17日星期二的交易中出售了25,000股该公司股票。股票以118.99美元的平均价格出售，总成交金额为2974,750.00美元。出售完成后，首席执行官现在拥有该公司55,144股，价值6,561,584.56美元。关于这次销售的披露可以找到这里。公司内部人士持有该公司3.40%的股份。
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its position in Prometheus Biosciences by 2,632.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,366,426 shares of the biopharmaceutical company's stock worth $38,574,000 after purchasing an additional 1,316,426 shares in the last quarter. State Street Corp lifted its stake in Prometheus Biosciences by 226.9% in the third quarter. State Street Corp now owns 1,586,074 shares of the biopharmaceutical company's stock valued at $93,594,000 after buying an additional 1,100,857 shares during the last quarter. Fred Alger Management LLC lifted its stake in Prometheus Biosciences by 325.5% in the third quarter. Fred Alger Management LLC now owns 1,036,165 shares of the biopharmaceutical company's stock valued at $61,144,000 after buying an additional 792,620 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Prometheus Biosciences by 164.7% during the second quarter. Woodline Partners LP now owns 1,191,661 shares of the biopharmaceutical company's stock valued at $33,641,000 after purchasing an additional 741,403 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Prometheus Biosciences by 26.6% during the third quarter. Vanguard Group Inc. now owns 1,561,606 shares of the biopharmaceutical company's stock valued at $92,151,000 after purchasing an additional 328,397 shares during the period. 78.31% of the stock is currently owned by hedge funds and other institutional investors.
机构投资者和对冲基金最近增持或减持了该公司的股份。Point72 Asset Management L.P.在第二季度将其在普罗米修斯生物科学公司的头寸增加了2632.9%。Point72 Asset Management L.P.在上个季度额外购买了1,316,426股后，现在拥有这家生物制药公司1,366,426股股票，价值38,574,000美元。道富集团在第三季度增持了普罗米修斯生物科学公司的股份226.9%。道富集团目前持有这家生物制药公司1,586,074股股票，价值93,594,000美元，此前该公司在上个季度又购买了1,100,857股。弗雷德·阿尔杰管理公司在第三季度将其在普罗米修斯生物科学公司的持股比例提高了325.5%。弗雷德·阿尔杰管理有限责任公司现在拥有这家生物制药公司1,036,165股股票，价值61,144,000美元，上个季度又购买了792,620股。Woodline Partners LP在第二季度增持了普罗米修斯生物科学公司的股票164.7%。Woodline Partners LP现在拥有这家生物制药公司1,191,661股股票，价值33,641,000美元，在此期间又购买了741,403股。最后，先锋集团在第三季度增持了26.6%的普罗米修斯生物科学公司的股票。先锋集团现在持有这家生物制药公司1,561,606股股票，价值92,151,000美元，在此期间又购买了328,397股。78.31%的股票目前由对冲基金和其他机构投资者持有。
About Prometheus Biosciences
关于普罗米修斯生物科学公司
(Get Rating)
(获取评级)
Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.
普罗米修斯生物科学公司是一家生物制药公司，致力于治疗炎症性肠病(IBD)的新型疗法和伴随诊断产品的发现、开发和商业化。它的主要产品包括PRA023，一种人源化的IgG1单抗(MAb)，正处于IIa期临床试验，用于治疗溃疡性结肠炎和克罗恩病，以及系统性硬化症相关的间质性肺疾病。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Prometheus Biosciences (RXDX)
- Bed Bath & Beyond Is Circling the Drain
- Allegro Microsystems Is A Well-Positioned Semiconductor Stock
- Scotts Miracle-Gro Hits Bottom, Reversal In Play
- Altria is a Great Recession Stock, Long-Term Outlook Uncertain
- Novavax Shares Jumped in January While Others Slipped
- 免费获取StockNews.com关于普罗米修斯生物科学的研究报告(RXDX)
- Bed Bath&Beyond正在绕着排水沟走
- Allegro MicroSystems是一只定位良好的半导体股票
- 斯科特奇迹-Gro触底，比赛逆转
- 奥驰亚是一只大衰退的股票，长期前景不确定
- Novavax的股价在1月份大幅上涨，而其他股票则出现下滑
Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普罗米修斯生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对普罗米修斯生物科学公司和相关公司的最新新闻和分析师评级的每日简要摘要。